Wireless Retinal Implant Restores Sight for Macular Degeneration Patients
Here’s a breakdown of the key information from the provided text,focusing on the PRIMA system for restoring vision in patients with geographic atrophy due to age-related macular degeneration (AMD):
What is the PRIMA System?
* Purpose: A subretinal prosthesis designed to restore central vision in patients with geographic atrophy (GA),an advanced form of dry AMD.
* How it Works:
* Bypasses damaged photoreceptors.
* Stimulates retinal bipolar cells.
* A tiny wireless implant is surgically placed under the retina.
* Paired with special glasses:
* A camera captures visuals.
* Near-infrared light transmits information to the implant.
* The implant converts images into electrical signals sent to the brain.
* Glasses have zoom and contrast adjustment features.
* Developer: Science Corporation, with collaboration from Stanford Medicine and other academic institutions.
the PRIMAvera Study (Clinical Trial)
* Published in: The New England Journal of Medicine
* Design: Open-label, multicenter, single-group, baseline-controlled trial.
* Participants: 38 enrolled, 32 assessed at 12 months.
* Evaluation:
* Visual acuity improvement.
* Safety (adverse events related to surgery or device).
* Home use and integration into daily life (via a survey).
Key Findings
* Efficacy: 81% (26 out of 32) of participants showed a clinically meaningful improvement in visual acuity (≥ 0.2 logMAR) after one year.
Background on Geographic Atrophy (GA) & AMD
* AMD: A leading cause of blindness in older adults.
* GA: An advanced stage of dry AMD, causing irreversible vision loss due to the death of retinal cells.
* Current Treatments: Existing treatments (injections) don’t provide significant vision improvement, only slow progression.
* Problem: Loss of photoreceptors prevents light from being converted into signals the brain can interpret, creating blind spots.
In essence, the PRIMA system offers a promising new approach to restoring vision for individuals with geographic atrophy by directly stimulating the retina and bypassing the damaged photoreceptors. The PRIMAvera study demonstrates significant visual improvement in a large majority of participants.